Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Gender Dysphoria Epidemiology Insight

DelveInsight’s ‘Gender Dysphoria – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Gender Dysphoria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030


Gender Dysphoria: Understanding

DelveInsight’s gender dysphoria epidemiology report gives a thorough understanding of the condition by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for gender dysphoria in the US, Europe, and Japan. Moreover, the report covers detailed information on the gender dysphoria epidemiology scenario in seven major countries (US, EU5, and Japan).


Epidemiology Perspective by DelveInsight:

This section encompassing gender dysphoria epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The gender dysphoria epidemiology data are studied through all possible divisions to understand the Disease scenario in 7MM better. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.


Detailed Epidemiology Segmentation:

The gender dysphoria epidemiology covered in the report provides historical and forecasted epidemiology scenarios in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.


The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report:

  • The gender dysphoria report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • The gender dysphoria report and model provide an overview of the global trends of gender dysphoria in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of gender dysphoria in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of gender dysphoria.
  • The report provides the segmentation of the gender dysphoria epidemiology


Report Highlights:

  • 11-year Forecast of Gender Dysphoria Epidemiology
  • 7MM Coverage
  • Prevalence of gender dysphoria
  • Gender-specific prevalence of gender dysphoria
  • Comorbidities associated with gender dysphoria


KOL – Views:

We interview KOLs and include SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered:

  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to gender dysphoria?
  • What are the key findings pertaining to the Gender Dysphoria epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017–2030)?
  • What would be the total number of gender dysphoria patients across the 7MM during the forecast period (2017–2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
  • What are the disease risk, burden, and unmet needs of gender dysphoria?
  • What are the currently available treatments of gender dysphoria?


Reasons to buy:

The Gender Dysphoria Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Gender Dysphoria market.
  • Quantify patient populations in the global gender dysphoria market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Gender Dysphoria therapeutics in each of the markets covered.
  • Understand the magnitude of gender dysphoria population by its epidemiology.
  • The gender dysphoria epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.


Key Assessments:

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

 

1 Key Insights

2 Executive Summary of Gender Dysphoria

3 SWOT Analysis for Gender Dysphoria

4 Gender Dysphoria Market Overview at a Glance

4.1 Market Share (%) Distribution of Gender Dysphoria in 2017

4.2 Market Share (%) Distribution of Gender Dysphoria in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Definitions

5.3 Etiology

5.4 Gender identity and Development of Gender Dysphoria

5.5 Pathophysiology

5.6 Diagnosis

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 Total Prevalent Population of Gender Dysphoria

6.3 Assumptions and Rationale – 7MM

7 Country-wise epidemiology of Gender Dysphoria

7.1 The United States

7.1.1 Prevalence of Gender Dysphoria in the United States

7.1.2 Gender-specific Prevalence of Gender Dysphoria in the United States

7.1.3 Comorbidities Associated with Gender Dysphoria in the United States

7.2 Germany

7.2.1 Prevalence of Gender Dysphoria in Germany

7.2.2 Gender-specific Prevalence of Gender Dysphoria in Germany

7.2.3 Comorbidities Associated with Gender Dysphoria in Germany

7.3 France

7.3.1 Prevalence of Gender Dysphoria in France

7.3.2 Gender-specific Prevalence of Gender Dysphoria in France

7.3.3 Comorbidities Associated with Gender Dysphoria in France

7.4 Italy

7.4.1 Prevalence of Gender Dysphoria in Italy

7.4.2 Gender-specific Prevalence of Gender Dysphoria in Italy

7.4.3 Comorbidities Associated with Gender Dysphoria in Italy

7.5 Spain

7.5.1 Prevalence of Gender Dysphoria in Spain

7.5.2 Gender-specific Prevalence of Gender Dysphoria in Spain

7.5.3 Comorbidities Associated with Gender Dysphoria in Spain

7.6 United Kingdom

7.6.1 Prevalence of Gender Dysphoria in the United Kingdom

7.6.2 Gender-specific Prevalence of Gender Dysphoria in the United Kingdom

7.6.3 Comorbidities Associated with Gender Dysphoria in the United Kingdom

7.7 Japan

7.7.1 Diagnosed Prevalence of Gender Dysphoria in Japan

7.7.2 Gender-specific Prevalence of Gender Dysphoria in Japan

7.7.3 Comorbidities Associated with Gender Dysphoria in Japan

8 Treatment

8.1 Guidelines

 World Professional Association for Transgender Health (WPATH) Guidelines

 Endocrine Society Guidelines

8.2 Patient journey

8.3 Case Study

 Title: Transgender Care in the Primary Care Setting

8.4 Access to healthcare services, insurance coverage and its impact on Trans people

8.5 Discrimination, social stigma, and other social issues

9 Unmet Needs

10 Appendix

10.1 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables

Table 1: Summary of Gender Dysphoria Market, Epidemiology, and Key Events (2017–2030)

Table 2: DSM-IV versus DSM-5 diagnostic criteria

Table 3: Prevalent Population of Gender Dysphoria in 7MM (2017–2030)

Table 4: Prevalence of Gender Dysphoria in the United States (2017–2030)

Table 5: Gender-specific Prevalence of Gender Dysphoria in the United States (2017–2030)

Table 6: Comorbidities Associated with Gender Dysphoria in the United States (2017–2030)

Table 7: Prevalence of Gender Dysphoria in Germany (2017–2030)

Table 8: Gender-specific Prevalence of Gender Dysphoria in Germany (2017–2030)

Table 9: Comorbidities Associated with Gender Dysphoria in Germany (2017–2030)

Table 10: Prevalence of Gender Dysphoria in France (2017–2030)

Table 11: Gender-specific Prevalence of Gender Dysphoria in France (2017–2030)

Table 12: Comorbidities Associated with Gender Dysphoria in France (2017–2030)

Table 13: Prevalence of Gender Dysphoria in Italy (2017–2030)

Table 14: Gender-specific Prevalence of Gender Dysphoria in Italy (2017–2030)

Table 15: Comorbidities Associated with Gender Dysphoria in Italy (2017–2030)

Table 16: Prevalence of Gender Dysphoria in Spain (2017–2030)

Table 17: Gender-specific Prevalence of Gender Dysphoria in Spain (2017–2030)

Table 18: Comorbidities Associated with Gender Dysphoria in Spain (2017–2030)

Table 19: Prevalence of Gender Dysphoria in the United Kingdom (2017–2030)

Table 20: Gender-specific Prevalence of Gender Dysphoria in the United Kingdom (2017–2030)

Table 21: Comorbidities Associated with Gender Dysphoria in the United Kingdom (2017–2030)

Table 22: Prevalence of Gender Dysphoria in Japan (2017–2030)

Table 23: Gender-specific Prevalence of Gender Dysphoria in Japan (2017–2030)

Table 24: Comorbidities Associated with Gender Dysphoria in Japan (2017–2030)

List of Figures

Figure 1: SWOT Analysis

Figure 2: Etiology of Gender Dysphoria

Figure 3: Prevalent Population of Gender Dysphoria in 7MM (2017–2030)

Figure 4: Prevalence of Gender Dysphoria in the United States (2017–2030)

Figure 5: Gender-specific Prevalence of Gender Dysphoria in the United States (2017–2030)

Figure 6: Comorbidities Associated with Gender Dysphoria in the United States (2017–2030)

Figure 7: Prevalence of Gender Dysphoria in Germany (2017–2030)

Figure 8: Gender-specific Prevalence of Gender Dysphoria in Germany (2017–2030)

Figure 9: Comorbidities Associated with Gender Dysphoria in Germany (2017–2030)

Figure 10: Prevalence of Gender Dysphoria in France (2017–2030)

Figure 11: Gender-specific Prevalence of Gender Dysphoria in France (2017–2030)

Figure 12: Comorbidities Associated with Gender Dysphoria in France (2017–2030)

Figure 13: Prevalence of Gender Dysphoria in Italy (2017–2030)

Figure 14: Gender-specific Prevalence of Gender Dysphoria in Italy (2017–2030)

Figure 15: Comorbidities Associated with Gender Dysphoria in Italy (2017–2030)

Figure 16: Prevalence of Gender Dysphoria in Spain (2017–2030)

Figure 17: Gender-specific Prevalence of Gender Dysphoria in Spain (2017–2030)

Figure 18: Comorbidities Associated with Gender Dysphoria in Spain (2017–2030)

Figure 19: Prevalence of Gender Dysphoria in the United Kingdom (2017–2030)

Figure 20: Gender-specific Prevalence of Gender Dysphoria in the United Kingdom (2017–2030)

Figure 21: Comorbidities Associated with Gender Dysphoria in the United Kingdom (2017–2030)

Figure 22: Prevalence of Gender Dysphoria in Japan (2017–2030)

Figure 23: Gender-specific Prevalence of Gender Dysphoria in Japan (2017–2030)

Figure 24: Comorbidities Associated with Gender Dysphoria in Japan (2017–2030)

Figure 25: Male-to-female gender-affirmation surgical options

Figure 26: Female-to-male gender-affirmation surgical options

Figure 27: Female to male patient journey for Gender Dysphoria

Figure 28: Unmet needs for Gender Dysphoria

Forward to Friend

Need A Quote